Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Novel IGF-1R inhibitor BMS-754807 in phase I development

March 26, 2009

AVEO and Biogen sign definitive agreement for ErbB3-targeted antibodies

March 26, 2009

Combination of paclitaxel and cyclophosphamide is safe in patients with bladder cancer

March 26, 2009

Syndax Pharmaceuticals describes sirtuin modulators for cancer treatment

March 25, 2009

PF-0419789, mutant B-Raf inhibitor, synthesized at Pfizer

March 25, 2009

Rexahn receives FDA approval to begin phase II trials for Archexin in pancreatic cancer

March 25, 2009

Celsion receives orphan drug designation for ThermoDox in liver cancer

March 25, 2009

CD40L gene therapy shows promise in urothelial bladder cancer trial

March 25, 2009

Vertex Pharmaceuticals claims novel protein kinase inhibitors

March 24, 2009

Nereus Pharmaceuticals has begun a phase II trial of NPI-2358 in NSCLC

March 24, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...